Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
Waters (NYSE:WAT) and BD have announced a transformative $17.5 billion merger combining BD's Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction. The deal will create a leading life science and diagnostics company with expected 2025 pro forma sales of $6.5 billion and adjusted EBITDA of $2.0 billion.
The merger doubles Waters' total addressable market to $40 billion and increases annual recurring revenue to over 70%. The combined entity expects $345 million in annualized EBITDA synergies by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five. The transaction is expected to be accretive to adjusted EPS in the first year.
Post-merger, Waters' CEO Udit Batra will lead the combined company, which will maintain the Waters name and NYSE:WAT listing. BD shareholders will own 39.2% of the combined company, while Waters shareholders will retain 60.8%. The deal is expected to close around Q1 2026.
BD (NYSE: BDX) has appointed Bilal Muhsin as Executive Vice President and future President of its Connected Care segment, effective July 2, 2025. Muhsin, who will report to CEO Tom Polen, joins from Masimo where he served as COO during his 25-year tenure.
In this newly created role, Muhsin will lead BD's Connected Care strategy, focusing on advanced analytics and AI solutions alongside smart devices to enhance patient care efficiency. The appointment aligns with BD's transformation into a pure-play MedTech leader, emphasizing connected medication management, advanced workflow robotics, and smart monitoring solutions.
Muhsin brings significant expertise in medical engineering and software development, holding over 50 patents in Medical Systems Communication, Analytics, and Patient Monitoring Systems.
BD (NYSE: BDX) has announced the initiation of XTRACT, a patient data registry to evaluate real-world outcomes of its Rotarex™ Atherectomy System in treating peripheral artery disease (PAD). The registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with patient follow-ups at 30 days, 6 months, and 12 months post-procedure.
The Rotarex™ System is a minimally invasive device designed to remove both plaque and thrombus in peripheral arteries, serving as both an atherectomy and thrombectomy device. The study, led by Dr. Prakash Krishnan and Dr. Todd Berland, aims to assess the system's clinical performance in treating PAD, a condition affecting over 21 million Americans and 200 million people worldwide.
BD (NYSE: BDX), a leading global medical technology company, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 2:00 pm Eastern Time. Investors and interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay of the presentation will be made available on the same platform after the event concludes.
BD (NYSE: BDX) has announced it will host an audio webcast on August 7, 2025, at 8 a.m. ET to discuss its third quarter fiscal 2025 financial results. The quarter ends on June 30, 2025. During the webcast, management will present the quarterly financial performance and provide updates on the company's operations and strategy.
The webcast will be accessible through BD's investor relations website, with presentation materials and a summary of financial information to be released prior to the call. A replay of the webcast will be available on the same website shortly after the event.
BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its upcoming participation in the Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time.
Investors and interested parties can access the live webcast through the BD investor relations website at investors.bd.com. For those unable to attend the live presentation, a replay will be made available on the same platform after the event concludes.
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced its latest quarterly dividend declaration. The company's Board of Directors has approved a quarterly dividend of $1.04 per common share.
Key details of the dividend announcement:
- Payment Date: June 30, 2025
- Record Date: June 9, 2025
- Annual Dividend Rate: $4.16 per share
This dividend announcement from the NYSE-listed company (BDX) demonstrates BD's commitment to providing regular returns to its shareholders.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
